Zydus Cadila gets USFDA nod to mineral supplement Potassium Chloride ER Tablets
Advertisement
Ahmedabad: Drugmaker, Zydus Cadila recently announced that the company has received final approval from the US Food & Drug Administration( USFDA) to market Potassium Chloride Extended-Release Tablets, a mineral supplement used to treat or prevent low amounts of potassium in the blood. The product in the strengths of 10 mEq (750 mg) and 20 mEq (1500 mg) will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.